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Summary
The cost effectiveness of reusable vs. single-use flexible bronchoscopy in the peri-operative setting has yet to be
determined. We therefore aimed to determine this and hypothesised that single-use flexible bronchoscopes
are cost effective compared with reusable flexible bronchoscopes. We conducted a systematic review of the
literature, seeking all reports of cross-contamination or infection following reusable bronchoscope use in any
clinical setting. We calculated the incidence of these outcomes and then determined the cost per patient of
treating clinical consequences of bronchoscope-induced infection.We also performed amicro-costing analysis
to quantify the economics of reusable flexible bronchoscopes in the peri-operative setting from a high-
throughput tertiary centre. This produced an accurate estimate of the cost per use of reusable flexible
bronchoscopes. We then performed a cost effectiveness analysis, combining the data obtained from the
systematic review and micro-costing analysis. We included 16 studies, with a reported incidence of cross-
contamination or infection of 2.8%. In the micro-costing analysis, the total cost per use of a reusable flexible
bronchoscope was calculated to be £249 sterling. The cost per use of a single-use flexible bronchoscope was
£220 sterling. The cost effectiveness analysis demonstrated that reusable flexible bronchoscopes have a cost
per patient use of £511 sterling due to the costs of treatment of infection. The findings from this study suggest
benefits from the use of single-use flexible bronchoscopes in terms of cost effectiveness, cross-contamination
and resource utilisation.
.................................................................................................................................................................
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Introduction
Flexible bronchoscopes allow visualisation of the
nasopharynx, oropharynx, larynx, trachea and its
subsequent divisions for diagnostic and therapeutic
purposes. It is estimated that 500,000 bronchoscopic
procedures are performed annually in the USA alone [1].
The risk of transmission of infection following bronchoscopy
with reusable flexible bronchoscopes is often under-
considered, even when they are reprocessed according to
infection control guidelines and recommendations [2–5].
However, the transmission of pathogenic organisms via
contaminated reusable flexible bronchoscopes remains an
evident risk [6–8], even if appropriate decontamination
procedures are adhered to [9]. There are unquantifiable
risks of cross-contamination and infection from reusable
flexible bronchoscopes, along with uncertainty regarding
© 2019 The Authors.Anaesthesiapublished by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists 529
This is an open access article under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs License, which permits use and
distribution in anymedium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
Anaesthesia 2020, 75, 529–540 doi:10.1111/anae.14891
their cost effectiveness. Reusable flexible bronchoscopes
are often used by anaesthetists to place tracheal tubes,
either awake or asleep, and to check adequate positioning
of double-lumen tubes. Therefore, cross-contamination risk
will also apply to these patients.
Single-use flexible bronchoscopes are delivered sterile
and thus should minimise the risk of infection transmission
and cross-contamination compared with reusable flexible
bronchoscopes. A previously reported cost effectiveness
study of single-use flexible bronchoscopes in a typical
intensive care unit (ICU) setting in the USA demonstrated
that subsequent implementation is cost effective when
looking at cross-contamination and potential subsequent
infection, and it is associated with increased patient safety
[10]. There are several reports of cross-contamination of
reusable flexible bronchoscopes due to inappropriate
cleaning, disinfection or lack of leak testing and drying
[11,12]. These reports do not provide a quantifiable risk for
cross-contamination and subsequent infection, but it is
accepted that there is a risk and cases are under-reported
[8, 13–15]; consequently, the literature lacks a quantified
risk of cross-contamination and subsequent infection due to
flexible bronchoscopy [8, 16, 17]. Moreover, several micro-
costing studies of reusable flexible bronchoscopes do not
include costs of infections, which is why there is some
uncertainty regarding these estimates [18–20].
We therefore aimed to determine the cost per use and
cross-contamination risk of reusable flexible bronchoscopes
and to ascertain the cost effectiveness of single-use flexible
bronchoscopes compared with reusable flexible
bronchoscopes in various clinical settings. To achieve this
we conducted a micro-costing analysis of flexible
bronchoscope utilisation from a high-throughput tertiary
centre [21] and a systematic review of the literature.
Our primary hypothesis was that single-use flexible
bronchoscopes are equally or more cost effective than
reusable flexible bronchoscopes.
Methods
The preferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidance was adhered to in the
conduct of the systematic review [22]. Given an evident risk of
patient cross-contamination and infection with reusable
flexible bronchoscopes [6,8] and no risk using single-use
flexible bronchoscope due to its single-use modality, the
effect measure in this cost effectiveness analysis was defined
as the avoided risk of infection using single-use compared
with reusable flexible bronchoscopes. A comprehensive
search strategy was conducted of the PubMed, MEDLINE and
Embase databases to identify relevant literature for the risk of
cross-contamination and infection associated with reusable
flexible bronchoscopes. The following search terms or
combinations were employed: ‘bronchoscopy’;
‘bronchoscope’ determine ‘infection’ determine ‘cross-
infection’ determine ‘pseudo-outbreak’ determine ‘outbreak’
determine ‘device contamination’ determine and ‘hospital
infection’, including word variations and assorted
permutations. English-language studies on humans were
included from 1982 to 2018. Retrospective and prospective
observational studies were included when studying the risk of
cross-contamination and infection post-bronchoscopy.
Reference lists of review articles were hand-searched to
locate studies that may have been missed in our initial search.
Eligibility criteria of studies were met if cross-contamination of
patients who underwent bronchoscopic procedures was
detected by traditional typing systems based on phenotypes
or more recent methods that examine the relatedness of
isolates at a molecular level, such as polymerase chain
reaction or pulse-field gel electrophoresis [23]. To quantify
the risk of infection, we needed the number of:
bronchoscopic procedures; patients who underwent
bronchoscopy; contaminated patients; and infected patients.
Studies were included in the quantitative analysis if at least
three of these four variables were reported. Studies were
excluded if they had a non-quantifiable risk. A study with a
non-quantifiable risk was defined as one in which less than
three of the above-mentioned parameters were reported.
Other exclusion criteria were other endoscopic procedures
(e.g. gastroscopy), if bronchoscope contamination was not
detected or reported by recognised typing methods, or if the
setting of the studies was not clinically relevant for answering
our hypothesis. The risk of infection was used as the
measurement of effectiveness. In the event of incomplete
data on the number of bronchoscopic procedures and
number of patients included, a simple regression method
was applied to predict missing data in this large
heterogeneous group of patients eligible for bronchoscopy.
The relationship was used to predict missing data points
within these two variables. Once regression methods were
applied, all studies were included for quantitative synthesis.
The risk of cross-contamination and infection was determined
by a weighted average using a fixed-effects model to reflect a
more precise estimate. There are currently no reported
cases of cross-contamination using single-use flexible
bronchoscopes, which is why the risk is expected to be 0%.
The cost effectiveness of single-use vs. reusable flexible
bronchoscopes was estimated by using a literature review
to obtain the best available evidence of effects. The effect
measure was the risk of infection. The time horizon of
the cost-effectiveness analysis was within 1 year. The
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micro-costing analysis was conducted at Guy’s and St.
Thomas’NHS Foundation Trust Department of Anaesthesia.
The total cost per use of reusable flexible bronchoscopes
for tracheal intubation and double-lumen tube position
verification was estimated, and the cost per use of single-
use flexible bronchoscopes (including the monitor) was
determined. All costs identified were adjusted to pounds
sterling (£) in 2017. To determine the present value of
capital expenditures, a discount rate of 3.5% was used.
Capital acquisition costs were annualised across a 5-year
period for bronchoscopes and related equipment, and a
30-year period for buildings.
A decision tree was constructed using Tree Age (2016
version, TreeAge Software, MA, USA), which enabled the
comparison of the cost effectiveness of single-use flexible
bronchoscopes to reusable flexible bronchoscopes (Fig. 1).
The modelling approach was based on principles of good
practice for decision analytic modelling in healthcare
analyses [24].
The cost perspective used in this analysis was a UK
government third-party payer, and the clinical setting was
an anaesthetics department where tracheal intubations and
double-lumen tube position verification were frequently
carried out. Multiple bronchoscopies for either tracheal
intubation or double-lumen tube position verification were
examined to determine the resources and costs associated
with the procedures. The procedures were monitored in
detail from start to finish.
Data obtained retrospectively from various fiscal years
(2000–2017) were used to quantify costs for capital
acquisitions, repairs, consumables, disposables and service
agreements. Additionally, labour time associated with the
reprocessing cycles of the reusable flexible bronchoscopes
was meticulously measured. The department has 19
reusable flexible bronchoscopes. Of these, 12 are used for
tracheal intubation (either awake or asleep), whereas seven
are reserved for double-lumen tube position verification.
The activities of performing bronchoscopy are dispersed
across various operating theatres on one floor, whereas the
reprocessing is divided on two different floors. The reusable
flexible bronchoscopes undergo a precleaning cycle on the
same floor as the operating theatre using equipment
including detergents and brushes, followed by a second-
stage manual clean performed in a central cleaning facility
on another floor. Costs were estimated using the mean
annual number of bronchoscopic procedures and
reprocessing volumes done by the automated endoscope
reprocessors in this tertiary hospital.
In the Supporting Information (Data S1), all collected cost
data from the micro-costing analysis are presented in detail.
This includes: (1) capital and repair costs of reusable flexible
bronchoscopes and rack systems; (2) capital and repair costs
of reprocessing capital and additional equipment; (3) time
measurements of the specific reprocessing steps; (4) average
cost of labour-related reprocessing; (5) reprocessing
equipment and costs incurred; and (6) the allocation keys and
reason for usage [25].
The costs of the clinical outcome were determined by
identifying treatment costs related to the clinical
manifestations of a post-bronchoscopic contamination or
infection. The incidence of postoperative pulmonary
complications (including pneumonia and sepsis) is
estimated to be up to 23% in an unselected group of
patients having general anaesthesia [26]. This figure is
higher in patients undergoing thoracic or head and neck
surgery [27], which are the cohort of patients in whom
Figure 1 Decision treemodel used in this cost effectiveness analysis.
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flexible bronchoscopes aremost commonly used. However,
there are no data directly demonstrating bronchoscope-
induced cross-contamination or infection in these patients,
as infection is often assumed to be multifactorial. We were
therefore only able to use published data of infection and
cross-contamination from the ICU or elective endoscopy or
bronchoscopy population. The cost of the clinical outcome
was estimated from the studies that were included
according to the clinical manifestations that were reported
in included studies, such as respiratory tract infection
prophylaxis and therapy [28–36] and sepsis [33, 35]. In the
cohort of patients of interest for this study, we considered
ventilator-associated pneumonia, sepsis and community-
acquired pneumonia as suitable outcomes. The average
cost of ventilator-associated pneumonia was identified from
a review of 28 US community hospitals to be £25,426
sterling per patient [37]. From a systematic review of
hospital-related cost of sepsis, the treatment-related costs
were identified as £27,123 sterling per patient [38]. The
costs of inpatient and outpatient community-acquired
pneumonia were estimated from > 28,000 community-
acquired pneumonia episodes from a large US database
study at £13,151 and £1948, respectively, per patient [39].
The weighted average was defined as the treatment-related
costs per patient infected. This value was imputed in the
cost-effectiveness analysis. A summary of all costs and effect
inputs for the cost-effectiveness analysis is presented in
Table 1.
Using the results from the literature review and the
micro-costing analysis to compute the cost-effectiveness
analysis, a base-case result was generated. Sensitivity
analyses were undertaken to capture uncertainty within
parameters and to provide sufficient insight to decision-
makers. Uncertainty is captured through deterministic and
probabilistic sensitivity analyses. One-way (univariate)
sensitivity analyses were applied to all parameters in the
model to test its robustness by examining the impact on the
incremental cost effectiveness ratio. All cost parameters
were varied by  50%. Considering the average period of
an 8-month investigation across the 16 studies, the effect
parameters were varied from a low value of 0% risk to a high
value of 20% risk. A scenario analysis was conducted from a
previous Delphi approach to the general risk of patient
cross-contamination and infection [10]. Furthermore, the
impact of the incremental cost-effectiveness ratio was
observed by varying the amortisation period of capital
investments related to bronchoscopy materials to 10 years
from the previous 5 years.
The probabilistic sensitivity analysis quantifies the
overall uncertainty within parameters using pre-specified
distributions (Table 1). The modality of the probabilistic
sensitivity analysis was a second-order Monte Carlo
simulation with 10,000 iterations of the mean incremental
cost-effectiveness ratios. These 10,000 iterations were
drawn up in a cost effectiveness scatterplot to represent the
expected avoidance of infection risk using a single-use
comparedwith reusable flexible bonchoscopes.
According to International Guidelines in Health
Economics, the mean is used as it is the only relevant
measure for economic decision making [40]. In economic
calculations, we aim to capture the uncertainty of the
sample mean, that is, parameter uncertainty, rather than
variability or heterogeneity, that is, stochastic variability.
The uncertainty in the expected mean is the standard
error (SE) [40]. Consequently, we report all cost data as
mean (SE).
Table 1 Inputs for the cost effectivenessmodel. Base-case value, the standard error (SE) and the distribution are provided.
Parameters Base-case value (SE) Distribution
Effects
Risk of patient contamination using a reusable FB 0.153 (0.009) Beta
Risk of subsequent infection using a reusable FB 0.181 (0.018) Beta
Risk of patient contamination using a single-use FB 0.0 (0.001) Beta
Risk of subsequent infection using a single-use FB 0.0 (0.001) Beta
Costs
Capital cost per use of a reusable FB (reusable FB, stack systems, reprocessing capital) £116.4a (29.10) Gamma
Repair cost per use of a reusable FB (reusable FB, stack systems, reprocessing capital) £92.9* (23.20) Gamma
Reprocessing cost per use a reusable FB (labour time and equipment) £39.9* (10.00) Gamma
Cost of per clinical outcome [37–39] (per patient infection) £9,454 (£1,158) Gamma
Cost per use of a single-use FB, includingmonitor £220 (21.80) Gamma
aSE was not estimated. However, a conservative approach was taken by varying the parameter with a SE of 25%. FB, flexible
bronchoscope.
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Results
We identified 890 citations, of which 12 were duplicates.
Seven additional studies were considered through hand-
searching of two review articles [7, 8]. Across numerous
studies a non-quantifiable risk was identified [41–62], thus
not fulfilling the inclusion criteria for the quantitative
analysis. After screening based on title and abstract and
full-text review, we identified 16 studies for quantitative
analysis of the cross-contamination and infection risk
(Fig. 2) [12, 28–36, 63–68]. The setting of these studies
were patients who underwent bronchoscopy in a hospital
intensive care or respiratory unit setting, or during
bronchoscopy or endoscopy in the UK, USA, France, Spain,
Australia or Taiwan (Table 2). The study designs were
prospective observational and retrospective studies, and
the period of contamination and infection investigation of
patients undertaken was from one to 23 months [30, 33].
A total of 2351 patients underwent 3120 various
bronchoscopic procedures. Of these procedures, 476 cases
of patient contamination were detected. Eighty-six of these
patients were reported to have a bronchoscope-linked
manifestation of infection, including pneumonia or other
respiratory tract infection. Seven of the included studies
contained a missing data-point relating to the number of
bronchoscopic procedures (five studies) and the number
of patients who underwent a bronchoscopy (two studies)
Figure 2 Study flow chart.
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[12, 30, 31, 35, 63, 64, 68]. These missing data-points were
predicted using a linear regression method. There was a
strong correlation between the number of patients
who underwent bronchoscopy and the number of
bronchoscopic procedures (r = 0.92) (see Supporting
Information, Data S2). From this, 118 and 299 patients were
predicted, respectively, for two of the studies with a missing
data point [30, 68]. A strong correlation was also
demonstrated between the number of bronchoscopic
procedures carried out and the number of patients who
underwent bronchoscopy (r = 0.93). Five studies contained
a missing data-point in terms of number of bronchoscopic
procedures, which were therefore calculated as 163, 429,
27, 76 and 63, respectively [12, 31, 35, 63, 64].
From the included studies, the differentiation between
a pre-existing infection and a flexible bronchoscope-related
infection was determined using traditional bacterial
recognition or more recent methods that examine the
association of isolates at amolecular level (Table 2).
One thousand annual bronchoscopic procedures
are performed by the Department of Anaesthesia at
Guy’s Hospital. The reprocessing volumes by the
automated endoscope reprocessor were 10,075 cycles
per year. The results from the micro-costing analysis
revealed a mean (SE) capital cost per use of a reusable
flexible bronchoscope at £116.40 (£29.10), whereas the
repair and reprocessing cost per use of a reusable
flexible bronchoscope was estimated at £92.90 (£23.20)
and £39.90 (£10.00), respectively. This equates to a
total cost per use of a reusable flexible bronchoscope
at £249.20 sterling. The mean (SE) cost per use of a
single-use flexible bronchoscope were provided by
Ambu (Ambu aScopeTM 4, Copenhagen, Denmark) at
£220.00 sterling (£21.80), including the monitor.
In the Supporting Information (Data S1), a detailed
overview and description are provided of all costs incurred,
and the allocation keys that were employed to more
accurately reflect reality.
In the cost-effectiveness analysis, we found reusable
flexible bronchoscopes to have a mean (SE) cost per patient
of £511.00 sterling (£59.60), with an associated risk of
infection of 2.8%. Themean (SE) cost per patient with single-
use flexible bronchoscopes are estimated at £220.00
(£21.80) and a 0% risk of infection. Base-case results indicate
a net saving of £291.00 to hospitals and an avoided risk
of infection of patients undergoing bronchoscopy at
2.8% with single-use flexible bronchoscopes compared
with reusable flexible bronchoscopes. The base-case
incremental cost-effectiveness ratio is £10,505, which is
interpreted as the cost of avoidedpatient infection.
Varying cost inputs by  50% did not have a
significant impact on the expected value of the incremental
cost-effectiveness ratio, which varied from £15,232 to
£5,778. From Fig. 3, the cost parameter with the greatest
impact on cost effectiveness is the cost of clinical outcome,
whereas the parameter with the lowest impact is the
reprocessing cost per use of a reusable flexible
bronchoscope.
Considering the average of 8 months of investigation
across the 16 studies of patient contamination and infection,
one-way sensitivity results from the CEA and a scenario
analysis is presented in Table 3.
The probabilistic sensitivity analysis was indicative
of a potential net savings to hospitals ranging from
£34 to 577 sterling per use and eliminating the risk of
infection of approximately 1.71–4.07% using single-use
flexible bronchoscopes compared with reusable flexible
bronchoscopes (Fig. 4).
Discussion
This systematic review and cost-effectiveness analysis found
that single-use flexible bronchoscopes are cost effective
and associated with a lower risk of infection compared
with reusable flexible bronchoscopes. Sensitivity analyses
support these findings. Our systematic review
demonstrated that the risk of patient infection post-
bronchoscopy was 2.8%, with a cost per use of a reusable
flexible bronchoscope of £249 sterling and of a single-use
flexible bronchoscope of £220 sterling. Our cost-
effectiveness analysis demonstrated that reusable flexible
bronchoscopes have a cost per patient use of £511 sterling
due to the potential costs of treatment of infection.
The risk for patient contamination (15%) and infection
(18%) resulted in a 2.8% risk of patient infection post-
bronchoscopy. In a previous study, a Delphi approach was
used to estimate the general risk of patient contamination
(3.4%) and infection (21%) in critical care settings [10]. This
generated a risk of post-bronchoscopy infection of 0.7%.
The estimate from this present study (2.8%) is of high
accuracy because patient contamination and infection were
linked to bronchoscopes and the data were sourced from
international, multicentre settings with more than 2300
patients undergoing approximately 3100 various
procedures.
The cost per use of reusable flexible bronchoscopes for
tracheal intubation in a UK hospital carrying out 141 flexible
bronchoscope-assisted tracheal intubations annually was
previously estimated as £340 sterling [69]. In this present
study, the total cost per use of reusable flexible
bronchoscopes in an institution performing 1000 annual
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procedures was estimated to be £249 sterling. The cost per
use for capital, reprocessing and repairs are highly
dependent on local and clinical setting. The reprocessing
costs are dependent on the length of non-usage before
reusable flexible bronchoscopes need reprocessing again.
This is a variable time, but can be as low as 12 h [5]. Staffing
costs and use of productive working hours are also factors
that may have an economic impact. Furthermore, repair
costs per use of reusable flexible bronchoscopes are also
highly dependent on the local setting. McCahon and
Whynes conducted an analysis at a teaching hospital with
repair cost per use of £146 sterling [69], which contrasts to
the repair cost per use at Guy’s Hospital of £93 sterling. This
could be due to service agreements to cover repairs of all
capital equipment in some institutions but not others.
Finally, capital costs per use are dependent on economies
of scale advantages, that is, the volume of annual
bronchoscopies. Comparing McCahon andWhynes data to
that in Guy’s Hospital, the capital cost per use was £141 and
£114, respectively. Other costing analyses have been
conductedwith total cost per use ranging from £111 to £540
sterling [18–20]. From these studies, the clinical setting in
terms of capital and repair expenditures play an important
role when determining the capital and repair cost per use,
whereas the reprocessing costs were similar between
settings.
There are two main strengths of this study, the first
being the micro-costing analysis as the cost comparison
between reusable and single-use equipment is complex.
Numerous overhead cost elements must be considered,
and this study captures more than previous studies [18–20].
The other main strength is the fact that this is the first study
to identify risk of patient contamination and infection from
the published literature.
Figure 3 Tornado chart showingmultiple one-way (univariate) sensitivity analyses of cost input parameters varied by  50%.
The incremental cost-effectiveness ratio (ICER)midpoint is£10,505 sterling and is equal to the base-case result from the cost-
effectiveness analysis. Low values (blue) for cost of clinical outcome, capital, repair and reprocessing cost per use of a reusable
flexible bronchoscope increase the ICER, whereas high values (red) reduce the ICER. Low values (blue) for cost of a single-use
bronchoscope reduce the ICER, whereas high values (red) increase the ICER. FB, flexible bronchoscope.
Table 3 Base-case result and one-way sensitivity analyses of effect parameters.
Description
Difference
in cost
Difference
in effects
ICER (cost per avoided
patient infection)
Base-case £291 2.8% Dominant
One-way sensitivity of effects
Cross-contamination risk of 0% £29 Nodifference Dominant
Cross-contamination risk of 20% £371 3.6% Dominant
Infection risk of 0% £29 Nodifference Dominant
Infection risk of 20% £318 3.1% Dominant
One-way sensitivity of amortisation of capital investments
Capital investments amortised across 10 years £239 2.8% Dominant
Scenario analysis using estimates of cross-contamination and infection risk obtained fromaDelphi approach[10]
Cross-contamination risk of 3.38%and infection risk of 21.3% £97 0.7% Dominant
ICER, incremental cost effectiveness ratio.
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In general, cost analyses lack precision in terms of
including all relevant overhead costs [18–20]. This is difficult
to manage because numerous elements contribute to the
overall cost per use estimate, such as water consumption,
electricity, training of new personnel in cleaning techniques,
maintaining updated and compliant guidelines on
reprocessing, handling of automated endoscope
reprocessor cycle failures, among others. Moreover, the
cost of the tracking systems is often left out [18–20]. If all
relevant indirect and overhead costs were identified and
included in those analyses, evidently it would add to the
cost per use. To advance the precision of the cost per use
estimate in this present micro-costing analysis, some of the
overhead costs mentioned above could have been
included. If done so, it would have added to the cost
effectiveness of single-use flexible bronchoscopes.
Findings from sensitivity analyses of cost per use of single-
use flexible bronchoscopes and reusable flexible
bronchoscopes support the cost effectiveness of single-use
flexible bronchoscopes, even when varying cost parameters
 50%.
In the institution examined in this study, the availability
of reusable flexible bronchoscopes remains limited due to
the unplanned requirement for flexible bronchoscopes, the
additional time required for reprocessing and the ongoing
requirement for bronchoscopes to be repaired. Availability
was still an issue, thus investment in a subset of single-use
flexible bronchoscope for emergencies was undertaken.
The availability of single-use flexible bronchoscopes is
constant as long as stocks are replenished, but the
availability of reusable flexible bronchoscopes are
hampered by the need for reprocessing.
The environmental impact of clinical care is also an
element to consider. The disposable equipment, chemical
detergents, water, electricity, and other resources used
during the reprocessing cycles have an environmental
impact, whereas single-use flexible bronchoscopes are
disposed of after each use. From research comparing
carbon dioxide (CO2) emissions and resource consumption
from a single-use flexible bronchoscope (Ambu aScopeTM 4)
to a reusable flexible bronchoscope, results show that the
materials used for reprocessing are substantial when
comparing the two types of bronchoscopes [70]. The use of
cleaning materials and personal protective equipment
contributes to a comparable or potentially higher material
and energy consumption as well as emissions of CO2
equivalents and value of resource consumption for reusable
comparedwith single-use flexible bronchoscopes [70].
This study has several limitations. Our cost-
effectiveness analysis show that, ceteris paribus, the single-
use technology is superior in terms of costs and patient
safety, and amix of single-use and reusable equipment may
be the only realistic alternative. But not all overhead costs
related to reusable equipment will be possible to eliminate,
and the predicted savings may be smaller under such
circumstances. Further research should be conducted to
investigate the cost effectiveness of a mixed usage strategy
for single-use and reusable bronchoscopes. Another
potential limitation is that we were unable to perform a
formal risk of bias assessment of the included studies
Figure 4 Probabilistic sensitivity analysis with 10,000 iterations (blue) and the base-case value (red).
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as no appropriate, validated tool was suitable. An
additional limitation was that we included data from
patients presenting for outpatient bronchoscopy, who
may sometimes have systemic pathology, could be
immunocompromised and are, therefore, prone to infection
[6–8]. However, the cohort of patients sought in the micro-
costing analysis also included patients undergoing thoracic
surgical procedures and patients undergoing major head
and neck surgery, both of which may be associated with
high risk of infection transmission and immunocompromise.
Moreover, the risk of transmission of infection remains,
regardless of patient baseline characteristics. Furthermore,
our cost calculations are primarily relevant to the peri-
operative setting, but the published data used come from
outpatient bronchoscopic and critical care settings, and
therefore there may be some discrepancy that is
unaccounted for due to this assumption. There was
heterogeneity in the lengths of investigations (1–
23 months), patient contamination rates (4.6–58%) and
infection risk (0–100%) among included studies. The
variation was partly accounted for by utilising a fixed-effects
model. When varying risks of patient cross-contamination
and infection in the sensitivity analysis, single-use flexible
bronchoscopes remained financially superior to reusable
flexible bronchoscopes. In addition, one of the assumptions
that were made was that the risk of infection of single-use
flexible bronchoscopes was 0%. However, there always
remain unaccounted-for risks of infection transmission, even
with single-use flexible bronchoscopes, due to unsterile
operators and surrounding equipment or re-use in the same
patient [71]. Finally, there remains a previously unreported
risk of nosocomial infection from tracheal intubation in
elective patients who are not critically unwell and who are
intubated for a limited duration of time, which might
account for some of the incidence of infection after
bronchoscopy. However, given that there are virtually no
data reporting nosocomial infection in these settings, this
may have a limited impact on our data. Moreover, the data
we used on the published incidence of infection could be
secondary to tracheal intubation rather than the use of a
flexible bronchoscope. However, given that only 44 of the
included patients with evidence of infection were in critical
care settings, it is unlikely that the incidence of infection
could be primarily attributed to non-bronchoscopic
sources.
In conclusion, our systematic review has demonstrated
that the risk of patient infection following bronchoscopy
with reusable flexible bronchoscopes is significant,
warranting a need for guidelines on reprocessing to be
stricter to ensure greater patient safety [8, 9, 72]. The total
cost per use of a reusable flexible bronchoscope was
calculated to be £249. The cost per use of a single-use
flexible bronchoscope was £220 sterling.When considering
the risk of infection in the cost analysis, reusable flexible
bronchoscopes have a mean cost per patient of £511
sterling and an associated risk of infection at 2.8%. The
findings from this study suggest benefits of single-use
flexible bronchoscopes in terms of cost effectiveness, cross-
contamination and resource utilisation.
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